Anabolic androgenic steroid induced myocardial toxicity: an evolving problem in an ageing population.
Widespread use of anabolic androgenic steroid (AAS) abuse is a rapidly increasing public health concern with an expanding demographic. Previous studies and reports have been exclusive to young individuals at low risk for traditional, non-AAS associated, cardiovascular disease. To date, the impact of AAS use on older patients has not been well characterised. The patient herein presented documents a dramatic case of an older individual who developed decompensated heart failure secondary to illicit use of AAS, highlighting an evolving problem among a rapidly expanding demographic and illustrating that a) AAS, used to alter appearance or augment performance, is no longer an issue confined to young adults; b) older individuals with ageing myocardium may be particularly susceptible to AAS toxicity and may present with fulminate congestive heart failure; and that c) AAS abstinence coupled with traditional heart failure pharmacotherapy may be an effective treatment for this condition.
Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, United States.
Richard D
RD
Rothman
Rory B
RB
Weiner
Harrison
H
Pope
Gen
G
Kanayama
Adolph M
AM
Hutter
Michael A
MA
Fifer
G William
GW
Dec
Aaron L
AL
Baggish
D045930:Anabolic Agents / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D003937:Diagnosis, Differential; D004232:Diuretics / Q000627:therapeutic use; D015150:Echocardiography, Doppler; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D017706:Lisinopril / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D045930:Anabolic Agents; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D005665:Furosemide; D017706:Lisinopril